AstraZeneca has amplified its investment in the U.S. with a commitment of $50 billion for manufacturing and R&D projects over the next five years. The centerpiece is a major manufacturing facility in Virginia focused on small molecules, peptides, and oligonucleotides for its metabolic drug portfolio, complementing ongoing initiatives including an R&D center in Cambridge and cell therapy sites across several states. CEO Pascal Soriot highlighted the move as a demonstration of AstraZeneca's confidence in U.S. biopharma innovation and its goal to increase U.S. revenue contribution to 50% by 2030. This expansion coincides with challenges posed by upcoming pharmaceutical tariffs and reflects the industry's strategic shift toward domestic production.